Market Overview

Johnson & Johnson To Pay $300M In Punitive Damages In Olson Talc Cancer Case

Johnson & Johnson To Pay $300M In Punitive Damages In Olson Talc Cancer Case

Johnson & Johnson (NYSE: JNJ) has been ordered by a jury to pay $300 million in punitive damages to a woman who blamed her rare asbestos-related cancer on the company’s talc products.

The plaintiff is Donna Olson, who has mesothelioma in her lungs. Bloomberg said Johnson & Johnson faces more than 14,000 claims that its talc powder caused ovarian cancer and mesothelioma, a rare cancer linked to asbestos exposure.

Trials over the cancer claims tied to Johnson & Johnson’s talc-based powders first began in 2016. This New York verdict was the 10th win for talc plaintiffs.

A company spokesperson told Reuters the talc trial had "significant legal and evidentiary errors" which the company believes will warrant reversal amid appeal.

Johnson & Johnson's stock fell sharply following the news, but quickly rebounded. Shares traded around $131.07 at time of publication.

Related Links:

Analysts View Johnson & Johnson's Organic Growth Guidance As Conservative

Johnson & Johnson's Asbestos Woes: Experts Speak Up

Photo credit: Austin Kirk, Flickr

Posted-In: TalcNews Legal Media Best of Benzinga


Related Articles (JNJ)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at